No quarterly revenue total was found in KAIROS PHARMA, LTD.'s SEC filings.
Kairos Pharma, Ltd. (KAPA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-1.39M
+2.4% vs year-ago quarter
Operating cash flow
$-1.01M
-25.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.06
+25.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
23.70M
+14.2% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KAPA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1962011
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.4M | -$1.7M | -$1.4M | -$1.4M | -$1.5M |
| Net income | -$1.4M | -$1.7M | -$1.4M | -$1.4M | -$1.4M |
| Diluted EPS | -$0.06 | -$0.08 | -$0.07 | -$0.07 | -$0.08 |
| Operating cash flow | -$1.0M | -$1.0M | -$1.1M | -$838,000 | -$805,000 |
| Total assets | $4.5M | $5.7M | $6.5M | $8.1M | $6.7M |
| Stockholders' equity | $4.2M | $5.3M | $6.3M | $7.7M | $6.0M |
| Cash and investments | $2.6M | $3.7M | $4.5M | $5.6M | $3.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 3, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 21, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
All 125 Kairos Pharma, Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.